中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
22期
15-17
,共3页
肝硬化%脐血干细胞移植%肝功能
肝硬化%臍血榦細胞移植%肝功能
간경화%제혈간세포이식%간공능
Liver cirrhosis%Umbilical cord blood stem cell transplantation%Liver function
目的 探讨脐血干细胞移植治疗失代偿期肝硬化的早期临床疗效.方法 30例给予脐血干细胞移植治疗的失代偿期肝硬化患者作为治疗组,30例仅给予常规保守治疗的失代偿期肝硬化患者作为对照组,分别在治疗前及治疗后4,8周检测肝功能和凝血功能,观察不良反应发生情况.结果 治疗组治疗后8周总胆红素、白蛋白、凝血酶原时间较治疗前明显改善[(71.3 ±37.8)μmol/L比(107.3±53.2)μmol/L,(30.1±4.9) g/L比(27.5±5.1)g/L、(15.0±2.9)s比(16.7±3.9)s],差异均有统计学意义(P＜0.05);而对照组治疗前后各指标比较差异均无统计学意义(P＞0.05).脐血干细胞移植过程中未见明显不良反应.结论 脐血干细胞移植治疗失代偿期肝硬化是一种安全、有效的方法.
目的 探討臍血榦細胞移植治療失代償期肝硬化的早期臨床療效.方法 30例給予臍血榦細胞移植治療的失代償期肝硬化患者作為治療組,30例僅給予常規保守治療的失代償期肝硬化患者作為對照組,分彆在治療前及治療後4,8週檢測肝功能和凝血功能,觀察不良反應髮生情況.結果 治療組治療後8週總膽紅素、白蛋白、凝血酶原時間較治療前明顯改善[(71.3 ±37.8)μmol/L比(107.3±53.2)μmol/L,(30.1±4.9) g/L比(27.5±5.1)g/L、(15.0±2.9)s比(16.7±3.9)s],差異均有統計學意義(P＜0.05);而對照組治療前後各指標比較差異均無統計學意義(P＞0.05).臍血榦細胞移植過程中未見明顯不良反應.結論 臍血榦細胞移植治療失代償期肝硬化是一種安全、有效的方法.
목적 탐토제혈간세포이식치료실대상기간경화적조기림상료효.방법 30례급여제혈간세포이식치료적실대상기간경화환자작위치료조,30례부급여상규보수치료적실대상기간경화환자작위대조조,분별재치료전급치료후4,8주검측간공능화응혈공능,관찰불량반응발생정황.결과 치료조치료후8주총담홍소、백단백、응혈매원시간교치료전명현개선[(71.3 ±37.8)μmol/L비(107.3±53.2)μmol/L,(30.1±4.9) g/L비(27.5±5.1)g/L、(15.0±2.9)s비(16.7±3.9)s],차이균유통계학의의(P＜0.05);이대조조치료전후각지표비교차이균무통계학의의(P＞0.05).제혈간세포이식과정중미견명현불량반응.결론 제혈간세포이식치료실대상기간경화시일충안전、유효적방법.
Objective To explore the clinical eficacy of umbilical cord blood stem cell transplantation in treatment of decompensated cirrhosis.Methods Thirty patients with decompensated cirrhosis were given umbilical cord blood stem cell transplantation (treatment group) and 30 patients with decompensated cirrhosis were given traditional treatment (control group).Liver function and blood coagulation function was tested after 4,8 weeks treatment respectively,and adverse effects were recorded at the same time.Results After 8 weeks treatment,total bilirubin,albumin and prothrombin time in treatment group was improved compared with that before treatment[(71.3 ± 37.8) μ mol/L vs.(107.3 ± 53.2) μ mol/L,(30.1 ± 4.9) g/L vs.(27.5 ± 5.1) g/L,(15.0 ± 2.9) s vs.(16.7 ± 3.9) s],and there was significant difference (P ＜ 0.05).There was no significant difference in the index before and after treatment in control group (P＞ 0.05).No obvious adverse reactions were observed in the process of umbilical cord blood stem cell transplantation.Conclusion Umbilical cord blood stem cell transplantation is safe and effective in treatment of deeompensated cirrhosis.
